18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text

Medicine, Bioinformatics, Oncology +17

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations

Helen Young, R. Baum, U. Cremerius et al. · European Journal of Cancer · 1999 · 1.7K citations · Full text

Medicine, Oncology, Radiology +16

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28

Eleftherios P. Mamounas, John Bryant, Barry C. Lembersky et al. · Journal of Clinical Oncology · 2005 · 714 citations

Medicine, Oncology, Pharmacology +17